The trajectory of Viagra, initially marketed by copyright, presents a complex case study for stakeholders considering the pharmaceutical landscape . Although its early success and generation of billions in earnings , the patent end has opened the way for generic medications, significantly reducing profit opportunities. This shift raises questions a